Craving and drug reward: A comparison of celecoxib and ibuprofen in detoxifying opiate addicts
OBJECTIVE: Craving for substance abuse is a usual and complicated problem in patients, with opioid addiction, who are in their opioid cessation process. Craving has been added as one of the diagnostic criteria of substance use disorders in DSM-5. AIM: The present trial was intended to compare effects of celecoxib versus ibuprofen in reducing pain and in decreasing the desire to use opiates in patients undergoing opiate detoxification. (n=32). PATIENTS AND METHOD: A total of 32 patients (both inpatients and outpatients), who were undergoing opiate detoxification procedure entered this 4 week study. Subjects who suffered pain due to opiate withdrawal were randomized into two groups; group one received celecoxib 200 milligrams once daily and group two received ibuprofen 400 milligrams four times per day. Self-reported Desire for Drug Questionnaire (DDQ) was utilized at baseline and at the end of the study to evaluate changes in opiate craving. RESULTS: After 4 weeks of treatment, with either ibuprofen or celecoxib, significant improvements in pain and craving were noted in each group. However no significant difference between the two groups was observed after 4 weeks of treatment with celecoxib and ibuprofen. CONCLUSION: The study noted that both celecoxib and ibuprofen, reduce craving in patients with opiate craving after 4 weeks of treatment without any significant difference between the two groups. The results suggest further study of celecoxib and other NSAIDs in the maintenance treatment of opiate craving.
Niaura RS, Rohsenow DJ, Binkoff JA, Monti PM, Pedraza M, Abrams DB. Relevance of cue reactivity to understanding alcohol and smoking relapse. J Abnorm Psychol 1988; 97: 133-152.
McAuliffe WE, Gordon RA. A test of Lindesmith's theory of addiction: The frequency of euphoria among long-term addicts. AJS 1974; 79: 795-840. 3. Marlatt GA, George WH. Relapse prevention. Br J Addict 1984; 79: 261-273.
Jellinek E, Isbell H, Lundquist G, Tiebout HM, Duchene H, Mardones J, et al. The craving for alcohol. A symposium by members of the WHO Expert Committees on Mental Health and Alcohol. Q J Stud Alcohol 1955; 16: 34-66.
Poulos CX, Hinson RE, Siegel S. The role of Pavlovian processes in drug tolerance and dependence: Implications for treatment. Addict Behav 1981; 6: 205-211.
West R, Schneiders N. Craving for cigarettes. Br J Addict 1987; 82: 407-415.
Baker TB, Morse E, Sherman JE, editors. The motivation to use drugs: a psychobiological analysis of urges. Nebraska symposium on motivation: University of Nebraska Press; 1986.
Stewart J, De Wit H, Eikelboom R. Role of unconditioned and conditioned drug effects in the self-administration of opiates and stimulants. Psychol Rev 1984; 91: 251-268.
Tiffany ST, Wray JM. The clinical significance of drug craving. Ann N Y Acad Sci 2012; 1248: 1-17.
Bressan RA, Crippa JA. The role of dopamine in reward and pleasure behaviour–review of data from preclinical research. Acta Psychiatr Scand Suppl 2005; 14-21.
Salamone JD, Correa M. The mysterious motivational functions of mesolimbic dopamine. Neuron 2012; 76: 470-485.
Müller CP, Homberg JR. The role of serotonin in drug use and addiction. Behav Brain Res 2015; 277: 146-192.
Buisman-Pijlman FT, Sumracki NM, Gordon JJ, Hull PR, Carter CS, Tops M. Individual differences underlying susceptibility to addiction: role for the endogenous oxytocin system. Pharmacol Biochem Behav 2014; 119: 22-38.
Volkow ND, Morales M. The brain on drugs: from reward to addiction. Cell 2015 13; 162: 712-725.
Wikler A. Recent progress in research on the neurophysiologic basis of morphine addiction. Am J Psychiatry 1948; 105: 329-338.
Childress AR, McLellan AT, O'Brien CP. Abstinent opiate abusers exhibit conditioned craving, conditioned withdrawal and reductions in both through extinction. Br J Addict 1986; 81: 655-660.
Kozlowski LT, Wilkinson DA. Use and misuse of the concept of craving by alcohol, tobacco, and drug researchers. Br J Addict 1987; 82: 31-45.
Robinson TE, Berridge KC. The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res Brain Res Rev 1993; 18: 247-291.
Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000; 342:1946-1952.
Akhondzadeh S, Jafari S, Raisi F, Nasehi AA, Ghoreishi A, Salehi B, et al. Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial. Depress Anxiety 2009; 26: 607-611.
Sayyah M, Boostani H, Pakseresht S, Malayeri A. A preliminary randomized double–blind clinical trial on the efficacy of celecoxib as an adjunct in the treatment of obsessive–compulsive disorder. Psychiatry Res 2011; 189: 403-406.
Frolov RV, Ignatova II, Singh S. Mechanism of K v 2.1 channel inhibition by a selective COX-2 inhibitor SC-791—modification of gating. Brain Res 2010; 1359: 67-74.
Association AP. Diagnostic and statistical manual of mental disorders (DSM-5®). American Psychiatric Pub; 2013
Ekman EF, Fiechtner JJ, Levy S, Fort JG. Efficacy of celecoxib versus ibuprofen in the treatment of acute pain: a multicenter, double-blind, randomized controlled trial in acute ankle sprain. Am J Orthop (Belle Mead NJ) 2002; 31: 445-451.
Sachs CJ. Oral analgesics for acute nonspecific pain. Am Fam Physician 2005; 71: 913-918.
Franken IH, Hendriks VM, Van den Brink W. Initial validation of two opiate craving questionnaires: the Obsessive Compulsive Drug Use Scale and the Desires for Drug Questionnaire. Addictive behaviors 2002; 27: 675-685.
Hassani-Abharian P, Mokri A, Ganjgahi H, Oghabian MA, Ekhtiari H. Validation for Persian Versions of “Desire for Drug Questionnaire” and “Obsessive Compulsive Drug Use Scale” in Heroin Dependents. Arch Iran Med 2016; 19: 659-665.
Hawker GA, Mian S, Kendzerska T, French M. Measures of adult pain: Visual analog scale for pain (vas pain), numeric rating scale for pain (nrs pain), mcgill pain questionnaire (mpq), short‐form mcgill pain questionnaire (sf‐mpq), chronic pain grade scale (cpgs), short form‐36 bodily pain scale (sf‐36 bps), and measure of intermittent and constant osteoarthritis pain (icoap). Arthritis Care Res (Hoboken) 2011; 63: Suppl 11: S240-252.
Meyers LS, Gamst G, Guarino AJ. Applied multivariate research: Design and interpretation: Sage; 2006.
Dunbar SA, Karamov IG, Buerkle H. The effect of spinal ibuprofen on opioid withdrawal in the rat. Anesth Analg 2000; 91: 417-422.
Wise RA. The neurobiology of craving: Implications for the understanding and treatment of addiction. J Abnorm Psychol 1988; 97: 118-132.
Dembo G, Park SB, Kharasch ED. Central nervous system concentrations of cyclooxygenase-2 inhibitors in humans. Anesthesiology 2005; 102: 409-415.
Ciceri P, Zhang Y, Shaffer AF, Leahy KM, Woerner MB, Smith WG, et al. Pharmacology of celecoxib in rat brain after kainate administration. J Pharmacol Exp Ther 2002; 302: 846-852.
Beiche F, Scheuerer S, Brune K, Geisslinger G, Goppelt-Struebe M. Up‐regulation of cyclooxygenase‐2 mRNA in the rat spinal cord following peripheral inflammation. FEBS Lett 1996; 390: 165-169.